Genmab A/S (GMAB) on Decifer

Decifer ranks GMAB number 145 of 270 tracked names on durable business quality.

Why it ranks here

• It earns solid returns on the money it puts to work, around 9% and it turns most of its profit into real cash.
• Revenue is expected to grow about 18% a year, profits are expected to grow 47%, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power.
• and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• Revenue growing 18% a year and profits expected to grow 47% are capped by no worldview role and momentum of 17 out of 35.

The current read

The evidence on GMAB lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Next-Gen Genetic & RNA/Antibody Therapeutics: Platform breakthroughs in RNA interference, redosable gene therapy and antibody engineering are converting once-undruggable and orphan targets into commercial therapies.

Read the full GMAB research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.